Interleukin Genetics moved closer to patent protection for its PerioPredict genetic risk test as the U.S. Patent and Trademark Office issued a notice of allowance for a patent.
A notice of allowance means the Patent and Trademark Office believes an invention qualifies for a patent, but the process is not yet complete. The company was granted a patent in New Zealand for the product in July 2015.
PerioPredict produces genetic data that can lower a patient’s systemic inflammatory burden to reduce the risk of periodontitis and other chronic diseases, according to the company.
